Unhappy New Year For Incyte With Itacitinib Flop
JAK1 Inhibitor Fails In Steroid-Naiïve Acute GVHD
Incyte's hopes of reducing its reliance on Jakafi have suffered a blow after a Phase III trial of itacitinib failed. The stock has slumped and analysts are raising concerns about the company's ability to generate value from its hefty R&D investments.
You may also be interested in...
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.
Biotech hopes this initial approval will be followed by approvals of Pemazyre in bladder cancer, first-line cholangiocarcinoma and possibly even a tumor-agnostic indication for FGFR-mutated cancers.